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In a previous study a functional interaction between 
pemphigoid antibodies, pemphigoid antigen, serum com-
plement, 'and leukocytes was shown using the leukocyte 
attachment method for detecting immune complexes in 
skin. In the method, leukocytes suspended in fresh serum 
attached in a specific linear pattern to the dermal-epi-
dermal junction of skin sections pretreated with pem-
phigoid sera containing complement-binding anti-base-
ment membrane zone antibodies. In this study, the mech-
anism of the attachment reaction has been investigated 
using a modification of the method as a visual assay of 
leukocyte migration on skin. Using the visual assay it 
was shown that leukocyte attachment is dependent on 
directed migration of cells to the dermal-epidermal junc-
tion. Chemotaxis mediated by pemphigoid antibodies 
and fresh serum was confirmed by continuous observa-
tion, analysis of time-sequence photomicrographs of cell 
migration and cinematography. A requirement for leu-
kocyte migration in the standard leukocyte attachment 
assay was supported by showing that attachment could 
be inhibited by leukocyte "deactivation" and by treat-
ment of cells with the inhibitors of migration, cytochal-
asin B and colchicine. Using decomplemented sera, C2-
deficient serum and skin-antibody-complement inter-
mediates, leukocyte chemotaxis and attachment to the 
junction was shown to require complement and func-
tional evidence for activation via the classical pathway 
and a role for C5 demonstrated. These studies show that 
leukocyte attachment is dependent on chemotaxis and 
that pemphigoid antibody-mediated complement acti-
vation can support one (chemotaxis) and probably 2 
(immune adherence) inflammatory cell functions. Fur-
thermore, they provide additional functional evidence 
that pemphigoid antibodies may be important in the 
pathogenesis of cutaneous inflammation in bullous pem-
phigoid. 
There is abunda nt evidence that immune compl exes can 
cause inflammation by depositing or forming in tissues and 
activa t ing th e complement system. Studies of experimental 
immune complex diseases in animals and suspected immune 
complex disease in man have shown localization of complement 
components at sites of antigen-antibody deposition [1-4], hy-
percatabolism and conversion of complement components in 
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se rum a nd tissue fluids [5) and biologically active complem en t 
fragments at sites of immune complex-mediated tissue injury 
[6-7]. In several models of experimental immune complex dis -
ease, inflammation is significantly inhibited in animals geneti-
cally deficient or artifically depleted of complement compo-
nents [2,7 -1OJ. 
The mechanism(s) whereby complement activation ca uses 
cellular inflammation and tissue injury is not fully understood 
but is thought to result in part from an interaction between 
biologicalJy active ti'agments of complement and leukocytes. 
For example, activation of complement by immune complexes 
in vitro has been shown to produce fa ctors which can mediate 
the directed migration (chemotaxis) of leukocytes [11-13], the 
recognition and attachment of leukocytes to t issues and parti-
cles coated with complement (immune adherence) [14,15] and 
fragments capable of stimulating phagocytosis and release of 
lysosomal enzymes [16,17]. 
From immunologic and histologic observations in patients 
and analogies to experimental immilne complex disease in ani-
mals, it has been proposed that immune complex-mediated 
complement activation contributes to the pathogenesis of cu-
taneous and mucous membra ne inflammation and blister for-
mation in bullous pemphigoid (BP) [18]. D eposits of immuno-
globu lin [19] and complement [20] have been detected at th e 
dermal-epidermal junction (DEJ) in perilesional t issue a nd 
histologic studies have shown leukocytes, often in large num-
bers, in the upper dermis a nd in contact with the DEJ at th e 
time structura l damage to the junction is seen [21]. These 
findings suggest that complement may be activated at the 
junction releasing mediators which can cause the accumula tion, 
localization and activation of leukocytes in skin. Supporting 
this assumption are the findings that most patients have serum 
antibasement membrane zone (BMZ) antibodies against a cu-
taneous BMZ antigen(s) and that most of these sera deposit 
complement (C3 ) at the junction of normal human skin in. vitro 
[22,23]. Evidence for localized complement activation in. vivo 
includes the findings that aU patients have components of the 
classic a nd a lternate pathways as well as complement regulating 
proteins at the site of t issue injury [24-27] and many have 
complement-derived chemotactic activity (probably C5a) [28] 
complement conversion products [24,29] and decreased comple-
ment levels in blister fluids [29]. 
In a recent study, evidence supporting a fun ctiona l inte rac-
Abbreviations: 
BMZ: basement membrane zone 
CB: cytochalas in B 
Co: colchicine 
CVF: cobra venom factor 
DEJ: dermal-epidermal junction 
DMSO: dimethylsulfoxide 
FITC: nuorescein isothiocyanate 
GBSS: Geys balanced salt solu tion 
MEM: Eagles minimal essential medium 
NHS: normal human serum 
PBL: peripheral blood leukocytes 
ZAS: zymosan-activated serum 
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tion between anti-BMZ antibodies, pemphigoid ant ige n, leu-
kocytes and serum complement was provided by showing that 
peripheral blood leukocytes (PBL) suspended in fresh normal 
human serum (NHS) would attach to the DEJ of skin treated 
with BP serum [30]. The reaction was shown using a method 
called "leukocyte attachment" in which cryostat sections of 
skin treated with BPS were placed between 2 microscope slides 
and overlaid with leukocytes by injecting between the slides a 
suspension of cells in fresh serum. After 30 min incubation at 
37°C, leukocytes were observed attached in a specific linear 
pattern at the DEJ . 
A requ irement for serum complement in the reaction was 
suggested by the findings that cells suspended in heat-inacti-
vated serum did not attach and only BPS containing-comple-
ment-binding anti-BMZ antibodies mediated the response. Fur-
thermore, a highly significant correlation was found between 
the titers of BPS mediating leukocyte attachment and comple-
ment (C3) binding titers. 
While the mechanism of leukocyte attachment was not de-
fined, a role for cell movement was suggested by the following 
observations: Though cells were observed to settle randomly on 
tissue following injection of the leukocyte suspension they were 
nonrandomly distributed on the junction at the completion of 
the incubation period; a relatively cell-free zone, 25- 50 fLm wide, 
was frequently observed on either side of the junction in positive 
experiments but not in controls and only viable leukocytes were 
able to attach to the junction . 
In later experiments it was observed that an attachment 
response identical to that seen with the standard attachment 
method occurred using a modified method . In the modified 
method skin sections treated with BPS were first incubated 
with leukocytes suspended in buffer to allow cells to adhere to 
skin and subsequently incubated for 30 min with NHS. In these 
experiments, it was confirmed that leukocytes remained ran-
domly distributed on skin in the absence of NHS bu t attached 
at t he junction when NHS was added. These studies provided 
additional evidence that components of fresh serum were re-
sponsible for initiating cell movement and suggested that com-
plement-mediated directed migration was a key factor in the 
attachment response. 
S ince the mechanism of leukocyte attachment could not be 
directly observed using the "standard leukocyte attachment 
method," the modified method has been used as a visual assay 
of cell migration to determine: (1) if BPS containing comple-
ment-binding ant i-BMZ antibodies could mediate the migration 
of l eukocytes to the DEJ, (2) whether migration was random or 
directed and (3) the role of complement in cell migration and 
a ttachment. Furthermore, evidence that complement-mediated 
chemotaxis is also a mechanism of cell attachment in the 
standard attachment method has been investigated by phar-
macologic inhibi tors of cell movement and complement-defi -
c i ent or complement-depleted reagents. 
MATERIALS AND METHODS 
Shill 
Fresh-frozen neonatal human foreskin was used as a source of skin 
in a ll studies. Foreskin obtained by routine circumcision of healthy 
neonates was trimmed of excess fat, washed gently for 5 min at 25 °C in 
sterile 0.15 M NaCI buffered with 0.01 M Na,PO., and NaHPO." pH 7.2 
(PBS), dried briefl y on Whatman No. 1 ftI ter paper (Fisher Scientific 
Co., Pi ttsburgh, PAl, quick-frozen in liquid N, and prepared for cryostat 
sectioning by embedding in Ames O.C.T. compound (Ames Co., Elk-
h art, IN) . All t issue was s tored at -70°C. Cryostat sections 8 fUll thick 
were cut prior to use on a H arris model WRC cryostat (Harris Manu-
facturing Co., Inc., Cambridge, MA) . 
Bullous Pemphigoid and Normal Human Control Sera 
Pemphigoid and normal human sera were collected by venipuncture, 
stored in 1.0 ml a liquots at -70°C, heat-inactivated (56 °C x 30 min) 
and diluted 1:10 in PBS prior to use. All pemphigoid patients had active 
disease and were diagnosed by previously reported clinical, histological, 
and immunohis tological criteria (27). For these studies, only BPS 
containing complement (C3) binding a nt i-BMZ antibodies were used. 
Peripheral Blood Lel.llwcytes (PBL) 
PB L from normal human donors were prepa red by dextran sedimen-
tation of heparinized whole blood using a previously described method 
[32]. Following dextran sedimentation for 30 min at 37°C, the leuko-
cyte-rich supernate was washed twice in 10.0 ml of Geys ba lanced salt 
so lu tion (Flow Labs, McLean, VA) conta ining 2% bovine serum a lbumin 
(GBSS + 2% BSA). Residua l red blood ce lls were not removed. Total 
leukocyte coun ts and percentages of mononuclear and granulocytic 
ce lls were obt.ained by examining methylene blue-sta ined ce lls in a 
hemocytometer. The percentage of granulocytic ce lls was a lways 70-
85%. Cell viability determined by trypan blue excl usion was consistent ly 
greater t han 98%. 
Inhibitor:; of Cell M igration 
Cytocha lasin B (CB) and colchicine (Co) were obtained from Sigma 
Chemical Co., St. Louis, MO. Stock solu t ions of both drugs were 
prepared by dissolving 2.0 mg CB or 100 mg Co in 1.0 ml dimethylsulf-
oxide (DMSO) (Fisher Scientific Co., Pittsburg, PAl and ftItering 
t h rough a Millex HA 0.45 11 fLl ter (MiLlipore Corp ., Bedford , MA) 
DMSO was requ ired to solubilize drugs in aqueous solu tions. Prior to 
use, inhibito rs were diluted in Eagles minimal essentia l medium (G ibco, 
Gra nd Island, NJ) conta ining Hanks Salts, I-glu tamine an d phenol red 
(MEM) to which was added 5% DMSO. T he final concentration of 
DMSO in working dilu t ions never exceeded 10%. 
Zymosan-a.ctivated Serum (ZAS) 
Just prior to use, NHS was activated by incubating 1.0 ml of serum 
with 10.0 mg zymosan (Sigma Chemical Co. , St. Louis, MO) fo r 30 min 
at 37°C. Zymosan was removed by centrifugation at 3000 rpm for 10 
min in a SOl'vall RC-2 refrigerated centrifuge. ZAS was t hen heat-
inactivated for 30 min at 56°C and used as described in a previous 
method to deactivate PBL [33]. 
Decomplemented normal human serum. Three 1.0 ml aliquots of 
NHS were depleted of complement by treatment with either heat--
aggregated (63 °C x 30 min) bovine gamma-globulin, Cohn Fraction II 
(S igma Chemical Co), zymosan or pW"ified Naja, naja cobra venom 
factor (CVF) obtained from Cordis Labs, Miami, FL. Decomplemen-
tation of serum with aggregated gamma-globulin and zymosan was 
performed by incubating 5.0 and 10.0 mg respectively in 1.0 ml serum 
for 30 min at 37°C followed by centrifugation and recovery of t he 
supernate [34]. Decomplementation with CVF was performed by in-
cubating 100 uni ts CVF in l.0 ml serum for 60 min at 30°C. Decomple-
mented sera were dilu ted to 1, 10, and 50% in GBSS + 2% BSA and 
used as described. 
Purified Complement Components and C2-deficient Serum 
Purified guinea pig C l , human C2, C3, C4 , C5, and C2 deficient 
human serum were the generous gift of Dr. S haun R uddy. Purified 
human C2 was a lso obtained from Cordis Labs. 
Shin·Antibody-Complement (SAC I423) Intermediates 
Cryostat sections of skin with bound pemphigoid antibody and the 
1st 4 components of complement (C1423) were prepared on glass slides 
by incubating 8 um cryostat sec tions of skin for 30 min at 21°C wi th a 
1:1 0 dilution of BPS No. 01 containing C3-binding anti-BMZ antibod ies. 
Serum treated sections were washed fo r 15 min in 3 changes of dextrose 
gelatin-verona l buffered sa line conta ining 5% dextrose, 0. 1% gelatin, 
0.15 mM CaC!" and 1.0 mM MgC!, (DGVB ++) . Afte r washing, sections 
were layered with 400 hemolytic uni ts of guinea pig Cl, 1000 hemolytic 
units of human C4 , 1000 hemolytic units of C2 which had been oxid ized 
with 1, [35] and 12.5 Ilg human C3 in a t.otal vo lume of 0.4 mIDGVB++ 
and incubated for 20 min at 21°C. Following incubation, slides were 
washed brieny with DGVB+;+-, excess moisture removed and used in 
the modified leukocyte attachment method as described. 
Indirect Imlll.llnofluorescence a.nd Indirect Complem.ent ·binding (C3) 
Imm.l1l1.o{luorescence 
IgG ant i-BMZ an tibody and C3-binding titers of pemphigoid and 
con trol human sera were measured using normal human skin as sub-
strate, flu orescein isothiocyanate (FITC) labeled antihuman IgG and 
C3 (Hyland Lab, Costa Mesa, CAl and previously described methods 
[22,361- The characteristics of antisera used were previously reported 
[27]. 
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Indirect Complement· binding (CS) Tmmunoflu orescence 
Th e binding of C5 to norma l human skin was assayed for all 4 
pemphigoid sera used in these studies. D eposition ofC5 was determined 
by incubating skin fo r 30 min with heat- inactivated BPS diluted 1:10 in 
PBS containing .15 mM Ca++ a nd 1.0 mM Mg++. Following three l5 
min washes in PBS; deposition of C5 at the OEJ was determined using 
a 2-step a ntibody technique. First, skin sections were incubated with a 
1:2 d ilu t ion of goat anti- huma n C5 (Kent La bs, Redmond, WA) for 30 
min and rinsed for 15 min in 3 changes of PBS. Second, sections were 
incubated with a 1: LO dilu t ion of FITC-labeled rabbit a nti-goat IgG 
(Cappel Labs, Inc., Cochranville, PAl for 30 min fo llowed by two 5 min 
rinses. FoUowing the fina l rinse, sec tions were examined with a Zeiss 
flu orescence microscope equipped with appropriate ruters. To contro l 
for the specific ity of the anti-C5 a ntisera , slides were prepared using 50 
J.Ll anti-C5 absorbed with 50 p.g purified C5. Immunochemica l cha rac-
teristics of the ra bbi t anti-goat IgG were: S pecific antibody concentra-
tions = 440 p.g/ul , FITC/protein ratio = 2.6. 
S tandard Leulwcyte Attachment M ethod 
Leukocyte attachment was performed on skin as previously described 
[30,371. B rie fly, two 8 um cryostat skin sections were placed in the 
center of gelatin -coated glass microscope s lides, a ir dri(!d a nd rinsed 
brie fly in PBS. Tissue was overla id with 50-100 p.l of heut- inactiva ted 
pemphigoid or normal cont rol se rum di.lu ted 1: to in PBS and incubated 
for 30 min at 4°C, rinsed in PBS and covered by a 2nd slide. The 2 
s lides were sepa rated by 2 thicknesses of vinyl tape (Fisher Scientific 
Co.) creating a chamber approximate ly 0.2 mm between the slides with 
a volume of approximate ly 0.4 ml. PBL were suspended in GBSS + 2% 
BSA containing 25% fresh NHS (se rum complement) to a final concen-
tration of 10 X LO" PBL/ ml and approximately 0.4 ml of the PBL 
suspension injected into the cha mbers. S lides were then incuba ted for 
30 min at 37°C. Following incuba tion, t issues were washed in cold PBS 
a nd examined wet by phase contrast microscopy at 250x or a ir-dried, 
fixed in 100% ethanol, stained with hematoxylin a nd eosin (H&E) a nd 
exam ined. Positive reactions were identified by a linear pattern of 
nonrandom leukocyte attachment at the OEJ over more than 50% of 
the junctional length. Negative reactions showed only random leuko-
cyte attachment. In some studies, leukocytes were pretreated wi th ZAS 
or inhibi to rs of cell motili ty prior to being injected into the cha mbers. 
In other studies, leukocytes were suspended in heat-inactivated (56 °C 
X 30 min) NHS, decomplemented NHS or serum genetically deficient 
in C2.· 
M odified Leulwcyte Attachment M ethod (Visual Assay of 
Chemotax is) 
A visual assay of leukocyte chemotaxis to the OEJ was developed 
using a modification of the leukocyte attach ment method as follows: 
Two 8 p.m cryostat sections of skin were placed in the center of a 
gelatin-coated microscope s lide and t reated as previously described 
with a 1:10 d ilu t ion of heat- inactivated pemphigoid or normal control 
serum. T he s lides were rinsed for 15 rnin in 3 changes of GBSS + 2% 
BSA, excess moisture removed and the tissues overla id with 100 p.l of 
PBL, LO X LO" ce lls/ m l, suspended in GBSS + 2% BSA. S lides were 
then incubated for to ·min at 37°C in a humidified a ir atmosphere to 
a ll ow leukocytes to attach to tissues a nd then non-adherent cells 
removed by rinsing slides gently for 5-10 min in GBSS + 2% BSA. 
Excess buffer was wiped away and the tissue wi th attached leukocytes 
covered with a 22 x 50 mm coverslip to which 2 thicknesses of vinyl 
tape were attached a t both ends. The tape prevented the covers lip 
from ma king contact with the tissue and cells and provided a space 
between s lid e and coverslip approximately 0.2 mm thick. The volume 
of t he space was approximately 0.3 ml. The s lide-coverslip preparation 
was placed on a heated (30-37°C) microscope stage and a portion of 
t he OEJ viewed by phase contrast microscopy at a magnification of 
250 x. After observing that leukocytes were randomly distributed on 
both s ides of the OEJ, a fie ld with 15- 25 PBL ra ndomly attached 
within approximate ly 50 11m on either side of the junction was identified 
a nd t he s lide-coverslip preparation injected with 0.3 ml of 25% pre-
warmed (30°C) fresh NHS or hea t- inactivated NHS diluted in GBSS 
+ 2% BSA. The migration of leukocytes was observed for 30 min and 
recorded by time sequ ence photom icrographs taken at 1 min in tervals 
us ing Ektachrome color fUm, ASA 200 (Eastman Kodak Co., Rochester, 
NY). In one series of exper iments, t he visua l assay of chemotaxis was 
performed using SAC1423 in termediates as the substrate to which 
leukocytes were a llowed to adhere. In these experiments, 0.3 ml of 
purified C5 (l00 p.g/m l of OGVB++) was injected in to the chambers 
a nd leukocyte migra tion visua lly assessed. 
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In terpretation of results of the visua l assay of chemotaxis. The 
resul ts of the chemotaxis experiments were assessed in the fOllowing 
ways: (J) visua l assessment. Cell migration was continuously observed 
for 30 min noting the position of leukocytes relative to the OEJ at the 
beginning of t he experiment, the direction of cell migration re lative to 
the junction during the experiment a nd the accumulation of PBL o n 
t he junction du ring and at the end of the experiment; visual assessment 
of m igration was made by 3 observers (WRG J C, CM) on at least one 
occasion a nd by one observer (WRG) on a ll occasions; (2) reconstruc_ 
Lion of ce ll movement us ing time sequence- photomicrography . Sequen_ 
t ia l (I -min in te rval) photomicrographs of ce ll migration were enlar ged 
to 5 x 7 inch prin ts and the prints used to make composite drawings 
showing the direction and distance moved for each cell during the 30-
min migration period. Analysis of cell migra tion was then performed by 
measuring the closest distance of each cell from th e junction at the 
beginning of the experiment (lD) and dividing by the actua l dis ta nce 
traveled (OT). Using the method of McCutcheon [38], ratio for each 
cell were expressed as ID/ DT and ass igned a positive (+) va lue if net 
movement was toward the junction a nd a negative (-) value if move-
ment was away from the junction (3) phase contrast cinematography. 
RESULTS 
Anti-BMZ Antibody, C3-B inding and L eukocyte Attachment 
Titers in Pemphigoid and Control Sera 
Four BPS and 2 normal human control sera were used in 
these studies. All sera were heat-inactivated (56°C x 30 min) , 
diluted 1:10-1:1280 with PBS and antibody, C3-binding and 
leukocyte attachment titers determined as described. Results 
recorded in Table I show that all BPS deposited IgG at t he 
DEJ at dilutions of 1:1280. In the presence of fresh NHS, all 
BPS deposited C3 at the DEJ at dilutions of 1:160- 1:320. No 
activity was detected in either of the 2 control sera tested at a 
1:10 dilu tion. All sera were subsequently used at a 1:10 dilution 
in the following studies. 
CS·Binding Activity in Pemphigoid Sera 
All 4 BPS deposited C5 at the DEJ in a linear pattern 
ident ical to t hat observed for anti-BMZ antibody and C3. The 
inte nsity of immunofluorescence varied from 1+-3+. Absorp-
tion of anti-C5 ant iserum with purified human C5 completely 
blocked C5 immunofluorescence confuming the specificity of 
the reaction. 
Effects of Decomplemented NHS on Cell Attachment Using 
the Standard L eulwcyte Attachment M ethod 
Cryostat sections of skin were treated with BPS No. 01 
(diluted 1:10) for 30 min and washed. Slides were then incubated 
with 0.4 ml of 10 x 10li PBL/ ml suspended in 1, 10, 50 or 100% 
concentration of: (1) fresh NHS, (2) fresh NHS decomple-
men ted with CYF, (3) fresh NHS decomplemented with Zym-
osan or (4) fresh NHS decomplemented with aggregated 
gamma-globulin. All experiments at each concentration were 
performed in duplicate and controls included fresh NHS which 
had been subjected to the same incubation time and tempera-
ture required for decomplementation. The results are shown in 
Table II. Using control sera, positive leukocyte attachment 
occw'red even at 1% serum concentrations. Furthermore, no 
significant difference could be observed between the attach-
ment reaction using 1% or 100% serum. No attachment of cells 
TABLE I. Anti-BMZ antibody, complement (C3) binding and 
leuhocyte a.ttachment titers in bullous p emphigoid and control sera 
Serum 
BPSOI 
BPS02 
B1'S03 
BPS04 
NHSl" 
NHS2" 
Anti -BMZ 
a ntibody 
> 1: 1280 
>1: 1280 
> 1 : 1280 
> 1: 1280 
NEG 
NEG 
" T ested at a 1: 10 dilution. 
Co mp leme nt (C3) 
binding 
1: 320 
1 : 160 
1 : 320 
1 : 320 
NEG 
NEG 
Le ukocyte 
aU,achmenL 
I : 320 
1 : 160 
1 : 160 
1 : 320 
NEG 
NEG 
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TABLE II. Effects of decomplemented and C-2 defr:cient serum on 
leukocyte attachment" 
Serum 
NHS 
NHS 
NHS 
NHS 
C2 defic ien t 
human serum 
C2 defi cient 
huma n serum 
T reatment 
Con tro l 
Decomplemen ted 
wit h Zymosan" 
Decomple mented 
with agg regated 
IgG 
D ecomplemented 
with CYF 
+ 400 hemoly tic C2 
" Standard method of leukocyte attachment. 
Concentration Leukocy te 
(%) attachment 
J 
10 
50 
100 
1 
10 
50 
100 
l 
10 
50 
100 
1 
10 
50 
100 
25 
25 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
/, 1 ml NHS + 10.0 mg zymosan incubated 30 min at 37°C, centrifuged 
400 xg and serum recovered. 
c 1 ml NHS + 5.0 mg heat-aggregated IgG, incubated 30 min at 37°C 
centrifuged to,OOO rpm , supernate recovered. 
to t he DEJ was observed when cells were suspended in any 
concentration of zymosan or aggregated gamma-globulin-
treated sera. Results with CVF -treated sera showed some at-
tachm ent at concent rations of 10, 50, and· 100% but no attach-
ment at 1%. Even though attachment could be observed at the 
higher concentrations of CVF-treated serum, the intensity of 
the reaction appeared to be less th an observed with equivalent 
concentrations of control serum. 
Effect of C2-deficient sera on leukocyte attachment using the 
standard leukocyte attachment method. In separate studies, 
the effect of C2-deficient serum was tested. For these studies 
PEL were suspended in 25% C2-deficient serum or 25% C2-
deficient serum reconstit uted with 400 hemolytic uni ts of puri-
fied huma n C2. In duplicate studies, attachment was observed 
with reconstituted serum but not wi th C2-deficient serum 
(Table II). 
Effects of cell "Deactivation" and Pharmacologic Inhibitors 
of Cell Migration on Cell Attachment Using the Standard 
Leulwcyte Attachment Method 
To fur ther establish a role for cell movement in the standard 
attachment method, 2 approaches were tried. In the first, PBL 
were pretreated with inhibitors of cell migration, by incubating 
20 X IOn PBL/ml in 1, 10, 50 or 100% ZAS or 100% fresh NHS 
as control. Fo llowing incubation with inhibitors or ZAS, cells 
were washed x 2 a nd suspended at 10 X 10(; PBL/ml in CBSS 
+ 2 % BSA containing 25% fresh NHS and tested in duplicate 
assays using the standard attachment method and skin sections 
prepared with BPS No. 01. Cell viability following alJ treatment 
methods was 98% or greater. Results of these studies showed 
t hat cells treated with Co attached in a dose-dependent fashion. 
Cells t reated with 10- :1 M Co fa iled to attach while cells treated 
with lO- f, M Co attached normally. Cells treated with 10-" M Co 
s howed attachment but the pattern differed somewhat from 
that seen in controls. In control experiments, cells were heavily 
con centrated at the junction producing a narrow linear band of 
cells 1-2 cell diameters wide . Cells treated with 10- 4 M Co, 
produced a band t hat was wider and less sharply d~fined. Cells 
treated with CB at alJ 4 concentrations failed to attach even 
though viabil ity as measured by trypan blue exclusion was 98% 
(Table III). 
TABLE III . E ffects of leu}wcyte deactivation a.nd inhibitors of cell 
migration on leukocyte attachlnent" 
Pretreatment of leukocytes ll Concentration of drug or serum 
Colchicine/ lO% DMSO 10- " molar 
10- < molar 
10-" molar 
Cytochalasin B/ l0% DMSO 1.25 1lg/ ml 
2.5O llg/ ml 
5.0Ilg/ ml 
15.0 Ilg/ ml 
Minimal Essential Media/ l0% DMSO 
Zymosan activated NHS' 1% 
10% 
50% 
100% 
NHS 100% 
" Standard method of leukocyte attachment. 
/, 20 x lOr; PBL/ ml incuba ted 30 min at 37°C. 
Le ukocyte at-
tachment. 
+ 
± 
+ 
+ 
+ 
+ 
' NHS activated with 10 mg zymosan/ ml NHS (30 min at 37°C). 
Cells deactivated with ZAS also showed a dose-dependent 
inhibition of attachment in that cells treated with 50 and 100% 
ZAS failed to attach but cells treated with 1 and 10% did attach. 
Control cells incubated in 100% NHS showed attachment 
(Table III). 
Assessmen.t of Directed Migration and Attachment of PBL to 
the Dermal-epidermal J unction Using the Modified 
Leu}wcyte Attachment Method 
To provide additional evidence that leukocyte attachment 
was dependent on cell migration, the modified leukocyte at-
tachment method was used as a visual assay of cell migration 
on skin sections treated with each of the 4 BPS containing 
complement-binding anti-BMZ antibodies. Each serum was 
tested on at least 2 occasions. Skin treated with each of 2 
normal human sera served as controls. 
In the first 1-2 min fo l1owing t he addition of fresh NHS 
(complement sOUl'ce) most cells began to show activity consist-
ing of membrane ruffling, cytoplasmic flow and pseudopod 
formation. Initially, pseudopod formation did not appear to be 
directed but by 5-10 min most cells on both the epidermal and 
dermal sides of the junction were observed moving toward the 
junction. Intermittently cells would stop moving, round-up and 
appear to rest for variable periods of t ime up to 1-2 min. 
Following t hese periods of inactivity cells would resume move-
ment toward the junction. Cells closest to the junction «25 
JLm) appeared to begin migration earlier, migrate more rapidly, 
show periods of inactivity less li-equently and follow a more 
direct path to t he junction compared to cells 25-50 JLm away. 
The majority of moving cells within 50 JLm of the junction 
eventually reached it during the 30 min observation period. 
Once cells reached the junction , t hey were observed to round-
up briefly , then extend pseudopods in both directions a long the 
junctional axis. In no case was a cell that had migrated to the 
junction observed migrating away from it. 
As greater numbers of cells reached the junction, it became 
increasingly visible due to the refractile properties of attaching 
leukocytes (Fig 1). T his was in striking contrast to the barely 
visible junction present at the beginning of the experiment. By 
t he end of incubatio n the, junction with attached cells was 
clearly visible and a relatively cell-poor zone, 25-50 JLm, on 
either side was appar ent in most experiments. In several studies, 
slides were processed for H&E following the visual assay oj 
chemotaxis and showed a linear distribution of cells along the 
junction identical to that seen in studies with the standard 
method (Fig 2). In control experiments using skin treated with 
either of the 2 normal human sera, no directed migration waE 
observed by visua l assay. 
In 4 of the chemotaxis experiments (one for each of the 4 
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FIG 1. A-D represents a se ries of phase contrast photomicrographs of a segment of derma l-epidermal junction (DEJ) taken at 5-10 min 
interva ls following the s~art of cell migration to t he junction. Note in A t hat the junction is poorly defined and leukocytes a re random ly distributed 
on the tissue. By following the sequence from A-D leukocytes can be observed moving from a random distribu tion to a nonrandom distribu tion 
on the junctian (seen best in D). As cells migrate to the junctian, it becames increas ingly visible presumably due to. the localization af refractile 
leukocytes. Sequential photographs such as these were used to construct the composite drawing shown in Fig 3. (x = 250). 
BPS) time- lapse photomicrographs were taken at I-min in ter-
vals and enlarged to 5 X 7 inch prints. Using the prin ts, a 
composite dl'awing (Fig 3) of cell positions relative to the 
junction, changes in position with time and direction of migra-
tion for most cells could be made. Using the composites, Mc-
Cutcheon ratios were calculated for all moving cells. Analysis 
of McCutcheon ratios confirmed· the results obtained by visual 
inspection. It can be seen from the results of 4 experiments 
(Table IV) that the average ratio (ID/ DT) of all moving cells 
was greater than 0.88 indicating a high degree of directed 
migra tion . Of interest was the finding that only one of the 51 
migrating cells in all 4 experiments migrated away from the 
junction. The distribution of McCutcheon ratios for the 51 
migrating cells is shown in Fig 4. 
Requirement for Fresh NHS in Directed Migration of PEL to 
the Dermal- epidermal Junction 
To show a requirement for fresh NHS (serum complement) 
in mediating directed migration of PBL to the junction, skin 
was incubated with each of 2 BPS (No. 01 and No. 02) previ-
ously shown to mediate directed migration. The chemotaxis 
assay was then performed by injecting 25% heat-inactivated 
(56°C X 30 min) rather than fresh NHS over the t issue. In 
duplicate experiments, cells were not observed to migrate to 
the junction; in fact, very li ttle migration occurred during the 
30-min observation period. To show that heat-inactivated NHS 
was not toxic for cells, 10 X 10" PBL were suspended in 1.0 ml 
of heat-inactivated NHS, incubated at 37°C X 30- 60 min and 
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F I G 2. Skin section stained with H&E fo llowing a chemotaxis exper-
ime nt. Note the lineal' attachment of leukocytes along the dermal-
e pidermal junction. This pattern of attachment is identical to that 
observed with the standard leukocyte attachment assay ( X =250). 
F 
FIG 3. A composite drawing prepared from time-sequence photo-
ITlicrograph of cell migration to the dermal-epidermal junction (DEJ). 
C h emotaxis experiment No. 1. The dots and arrows represent the 
locations and direction of movement for each of the 19 migrating ceLIs 
(A -S) during the 30-min migration period. Using compo ites such as 
t his, the distance of the cell from the junction at the beginning of 
ITligration (lD) , the actual distance traveled (DT) and final destination 
of the cells was established and used to calculate McCutcheon ratios 
(ID/ Dr) of cell movement shown in Table II. E = epidermis, D = 
dermis, SC = stratum corneum. 
viability assessed by trypan blue exclusion found to be greater 
than 98%. Furthermore, it was shown in a single experiment 
t hat cells incubated in heat-inactivated serum for 30 min could 
ITligrate to the junction in the presence of fresh NHS (resu lts 
not shown) . In addition, to these studies, 2 experiments were 
performed in which time lapse cinematography vividly dem-
onstrated the directed migration of leukocyte to the DEJ. 
Directed Migration of PBL on S ilin-Antibody-Complement 
Intermedia.tes in the Presence of C5 
To confll'ln a role fo r complement and determine if C5 could 
serve as a source of chemotactic factor in di.rected migration of 
cells to the DEJ, a classic complement path way C5 convertase 
was prepared on skin using BPS No. 01 and purified comple-
ment-co mponents C l , C4, C2 and C3. Afte r incubation of anti-
body- treated skin with the 1st 4 components of complement, 10 
x 10'; PBL in buffer were allowed to briefly attach to the skin 
sections, excess and nonadherent cells removed by gently wash-
ing and the visual assay of cell migration performed by injec ting 
either 0.3 ml of pUl'ifed C5 at a concentration of 100 }lg/ ml in 
DGVB++ 0 1' DGVB++ alone. Each experiment and control 
was performed in duplicate and observed by 2 separate inves-
t igators (J C and WRG). Resul ts show that PBL would migrate 
and attach to the DEJ in the presence of C5 but not buffer. 
DISCUSSION 
In a previous study we showed that PBL suspended in fresh 
NHS would attach in a specific lineal' pa ttern to the DEJ of 
skin sections which had been treated with BPS [30]. The 
requirement for fresh NHS a nd BPS containing complement-
binding anti-BMZ antibodies suggested that complement me-
diated immune adherence and cell migration were involved in 
the attachment reaction. Evidence that immune adherence 
a lone was not sufficient, was suggested by the findings tha t 
skin, leukocytes and fresh NHS had to be incubated simul ta-
neously for attachment to occur. If skin were fU'st incubated 
wit h BPS with or followed by fresh NHS and then washed, 
subsequent incubation with cells suspended in buffer did not 
cause attachment (data not shown) . Had immune ad herence 
been the only mechanism involved attachment would have 
been expected since it has been shown that cells with membrane 
receptors for IgG 01' complement will adhere to ant ibody and 
complement-coated tissue (including skin) or particles when 
incubated in the absence of fresh NHS [42-45). 
In la te r studies, a modification of the standard leukocyte 
attachment method was developed which differed from the 
original procedure only in the sequence with which cells and 
fresh NHS were added to antibody-treated skin. In the modified 
method, PBL, suspended in buffer instead of serum were a l-
lowed to settle on skin and nonad herent cells removed by gently 
washing sections in buffer. When sections were then incubated 
with fresh serum, leukocyte attachment to the junction indis-
tinguishable from that observed with the standaJ'd method was 
seen. If sections were incubated with heat-inactivated NHS or 
buffer, cells remained randomly distributed even after pro-
longed (60 min) incubation. These resul ts suggested that cell 
migra tion ini t iated by pemphigoid antibody-mediated comple-
ment activation was a requirement for leukocyte attachment in 
the method and that the same mechanism might be requu'ed in 
the standard method. 
In this study, evidence for dU'ected migration of PBL to the 
dermal-epidermal junction was obtained using both the stan-
daJ'd and modified leukocyte attachment methods. Evidence 
obtained with the standard method included the results of 
"leukocyte-deactivation" with zymosan-activated serum and 
treatment wi th inhibitors of cell migration, cytochalasin Band 
colchicine. Leukocyte deactivation is a phenomenon whereby 
cells incubated in the pres.ence of a chemotactic factor but in 
the absence of a concentration gradient of the factor gradually 
lose the ability to migrate when subsequently exposed to a 
gradient of the factor [39]. Deactivation is dependent on both 
the concentration of the chemoattractant and t he time cells are 
exposed to it . In these studies a dose-dependent inhibition of 
leukocyte attachment by incubation in Zymosan-activated se-
rum (a SOUJ'ce of complement-derived chemotactic factors) sup-
por ted a role for chemotaxis in attaclunent. 
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TABLE IV . Summwy of results of 4 experiments of leu}wcyte migration on shin 
Expe riment num · Pemph igoid 'To tal num ber cells T Ola l number cells % T OLal cells rni- M cCutcheon ratio for each migrating cell '· 
observed ll migrating" grllting ber serum 
01 23 18 83 0.92 0.89 0.50 1.00 0.61 0.91 0.75 
0.83 0.95 1.00 1.00 1.00 0.95 
1.00 0.90 0.82 0.86 0.93 
2 02 12 8 67 0.68 0.90 0.57 0.73 1.00 0.93 1.00 
1.00 
3 03 15 13 87 1.00 1.00 1.00 0.80 0.87 0.82 0.93 
1.00 0.95 l.00 0.84 0.92 0.94 
04 15 12 84 l.00 1.00 .750 1.00 0.50 1.00 - 0.53" 
0.89 0.89 0.88 0.62 1.00 
Summary of 
Average McCutcheon ratio for 51 migrating cells = 0.88 results 65 51 80 
" Tota l number of leukocytes observed within 50 I-' m of the DEJ (includes motile and non-motile cells). 
" Number of total migrating cells within 50 I-'m of t he DEJ. 
,. Hatio ca lculated dividing origina l distance of cell from the DEJ by the actua l dis tance moved during the 30-min observa tion period. 
d The only cell observed to move away from the DEJ-assigned a negative (-) ratio. 
18 
16 
14 
12 
..J 10 
en 
0.. 
~ · 8 
6 
4 
2 
1.00 .40 .20 0 .20 .40 .60 .80 1.00 
+ <E----- -----+ -
McCUTCHEON RATIO 
FIe 4. The distribu tion of McCutcheon ratios for the 51 migrating 
cells lis ted in Table II. 
Inhibition of attachment by preincubating cells in cytochal-
asin B and colchicine also supported cell migration. Cytochal-
asin B, a n inhibitor of microftlament function has been shown 
to be a potent inhibitor of both random and directed cell 
migration [39]. Colchicine is somewhat more selective. It is an 
inhibitor of microtubular function and has been shown to 
inhibit directed migration without significantly effecting ran-
dom migration [40,41]. 
To provide direct evidence for cell migration, the modified 
met hod of leukocyte attachment was used as a visual assay of 
leukocyte chemotaxis. The method is similar to previously 
reported "slide-coverslip" methods which have been used to 
examine leukocyte migration on glass to a variety of tissues and 
complement-activating particles [38,41]' The method provided 
an opportuni ty to continuously observe cell movement and 
obtain photographic records of events occurring when randomly 
distributed cells and fresh NHS were incubated simultaneously 
on BPS-treated skin sections. This was achieved by first allow-
ing cells to attach and following migration by direct observation 
and taking t ime-sequence photographs to help reconstruct the 
changes in the position of the cells relative to the DEJ . 
The preliminary incubation of skin sections and cells in buffer 
permitted removal of nonadherent cells (red cells, damaged 
cells, some lymphocytes) which obscured visualization of mi-
grating cells prior to adding NHS and permitted selection of 
segments of junction with optimal numbers of cells for analysis. 
Microscopic fi elds containing 10-25 cells positioned within 50 
Jlm of the junction were chosen since migration of larger num-
bers of cells a nd cells located further from the junction was 
difficult to follow. 
Using time sequence photographs, migrat ion, direction of 
migration, and eventual destination of cells was confirmed. By 
measuring the actual distance traveled on composites and di-
viding by t he closest distance between cell and junction at the 
beginning of cell movement, a McCutcheon ratio representative 
of the "directedness" of cell migration was determined for all 
moving cells. The compiled results of four experiments using 4 
BPS showed that 51 (80%) of 65 cells originally located with 50 
Jlm of the junction demonstrated migration. Of the 51 migrating 
cells, 50 (98%) migrated to the junction with an average M c-
Cutcheon ration of .88 (range 0.50-1.00). For unknown reasons, 
22% of cells did not migrate . Possibly these were damaged 
during the procedure or belonged to a slow or non migrating 
population of cells. Evidence that chemotaxis was specific for 
serum containing ant i-BMZ antibodies was demonstrated by 
showing that cell migration did not occur on sections treated 
wit h normal human sera. 
Rather than exclude a role for immune adherence in cell 
attachment, these results suggest that cells must migrate from 
a random position on skin before adherence can occur. It is 
reasonable to assume that cells migrating to the junction do 
attach by immune adherence once they arrive. This sequence 
of events, chemotaxis followed by adherence, is probably r ep-
resentative of in vivo events occuning when complement is 
activated on particles or t issues. In view of the well-established 
affinity of human neutrophils [46,47], eosinophils [48,49] and 
monocytes [50] for particles coated with IgG antibody and 
activated complement, particularly C3b; the demonstrated 
presence of IgG and C3 at the junction and these studies 
showing that pemphigoid antibodies form a functional comple-
ment-activating immune complex, it would be difficult to imag-
ine that immune-media ted leukocyte adherence is not involved 
in attachment. 
The evidence obtained from this and a previous study [30] 
using both methods of cell attachment show that BP antibodies 
can activate complement at the junction and that activation is 
required for both chemotaxis and attachment. The evidence 
includes: (1) a requirement for complement-binding pemphigoid 
sera; (2) a requirement for fresh but not heat-inactivated serum; 
(3) a strong correlation between complement-binding C3 and 
leukocyte attachment t iters; (4) absence of attachment with 
C2-deficient serum; (5) directed cell migration on SAC1423 
intermediates in the presence of purified C5, and (6) failure of 
attachment using NHS decomplemented with aggregated 'IgG 
or zymosan. The fa ilure of high concentrations of NHS dec om-
plemented wi th CVF to block attachment may have been due 
to incomplete decomplementation, however, residual comple-
men t activity in those sera was not tested by other methods. 
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Results of C5-binding immunofluorescence and studies with 
SAC1423 interm ediates provide both immunohistologic a nd 
functional evidence th at complemen t activation proceeds at 
l east to C5 with th e formation of biologically active C5 frag-
ments which can mediate the directed migration of leukocytes 
to t h e junction. Presumably th e major C5-fragmen t involved is 
C5a which has been sh own to be t h e most active complement-
derived ch emotactic factor in ma n [51]. 
Resu lts of studies with C2-deficien t selUm and SAC1423 
intermediates a lso provide functional evidence t hat pemphigoid 
antibodies can activate complement by the classical pathway. 
Since only one BPS (No. 01) was used as t he source of antibody 
in t hese studies, it is not possible to generalize abou t th e 
pathway of complement activation by other sera but t hese 
results are consistent with previously reported immunofluores-
cence studies showing t h e most, if not all, complem ent -binding 
BPS do activate through t hat pathway [52,53]. 
While t h e relevance of t hese studies to the actual immuno-
logical a nd cellular events occurring in t h e disease remains to 
be establish ed, r esults using limited numbers of BPS do sh ow 
that: (1) complement-binding a nti-BMZ antibodies can form 
functio nal immune complexes at t h e DEJ; (2) th at t h e com-
plexes can activate complement producing biologically active 
intermediates and (3) that these interm ediates can support at 
least one, (chemotaxis), a nd probably 2, (immune adherence), 
cell functions t hough t to be of m ajor importance in infla mma-
tion. Furthermore, t h e results demonstrate a mechanism 
whereby immune complexes and complem ent can localize leu-
kocytes at th e junction, t h e major site of tissue damage in th e 
disease. 
Evidence t hat complement activation and complement -me-
diated leukocyte functions are important in the pathogenesis of 
BP is supported by t h e resul ts of previous serological, immu-
nofluorescent and histological studies on skin and blister fluids. 
Components of the early classical (Cl, C4) a nd alternate (Factor 
B, Properdin) pathways in addition to C3, C5, and t h e regulat-
ing protein Beta 1 H , have been detected in perilesional skin 
[24,25,26,30]. The presence of Factor B, properdin and B,H 
deposited with C3 would suggest that t h e active form of C3, 
C3b, is present since these components are known to bind to 
C3b in vitro [54-56]. The presence of C3b at t h e junction would 
be expected to mediate not only immune adherence a nd acti-
vation of leukocytes but participate in th e formation of t h e 
classic (C423b) a nd/or a lternate (C3bBbP) C5 convertases 
which could cleave C5 r eleasing C5a which has potent chemo-
tactic and a naphy latoxic activity [57,58]. Evidence supporting 
local activation of both pathways and generation of C3b and C5 
chemotactic and anaphylactoxic activity has been provided by 
studies of pemphigoid blister fluids [24,28,29,59,60]. 
In a ddition to t hese findings, histological and ultrastructural 
studies have shown that cellular inflammation in t he mid and 
upper dermis is a characteristic prebullous even t in most pa-
tients. These studies have demonstrated apparen t leukocyte 
migration from dermal blood vessels to t he DEJ, degranulation 
of cells at th e junction and leukocytes in apposit ion to th e 
junction concomitant with structural damage and early blister 
formation [21,60]. It would appear likely based on t he combined 
immunological a nd histological studies in vivo and in vitro t hat 
pemphigoid antibody-mediated complement ac tivation is r e-
sponsible e ither directly or indirectly for t h e cellular events 
seen in t his disease a nd t hat cellula r inflammation m ediated at 
l east in part by complement activation at t he junction is re-
sponsible for many of t he histological and clinical features· of 
t h e illness. 
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